Skip to main content

Table 1 Clinical information table of the enrolled study

From: Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

  References Phase Sample size Mean age HLA Lymph node DTH (mm2)-case DTH (mm2)-control CD8+ T-cell (%)-case Recurrence (%) Overall survival (%) DFS (%)
Case Control Case Control Case Control Pre Post Pre Post Pre Post Case Control Case Control Case Control
GP2 aMittendorf [12]/Tommy [10] II 89 91 49 A2+ A2+ 51N+ 60N+ 4.1 15.3 3.9 8 0.8 1.5 5.12 2.35 92.13 95.6 82.9 80.4
Clifton [30] I 17 0 47 A2+, A3+   13N+   28 68    46*106 144*106       
Carmichael [11] I 18 0 47 A2+   18N   0 27.5    0.4 1.1       
GP2 Total 3 trials   124 91                  
E75 Clifton [7] II 136 139 51 A2+, A3+, A24+, A26+   81N+ 88N+ 1.6 7.9 2 2.1 0.025 0.09 8.82 14.4    89.8 83.8
Clifton [32] II 81 69 52 A2+, A3+, A24+, A26+ A2+, A3+, A24+, A26+ 49N+ 44N+             
Mittendorf [8] III 382 376 51.8 A2+, A3+ A2+, A3+ 373N+ 366N+        6.3 9.8    77.1 77.5
Mittendorf [9] I, II 108 79 55 A2+, A3+ A2, A3 53N+ 44N+ 1.2 13.7 0.4 1.7    10 20    89.7 80.2
Mittendorf [33] I, II 106 76 55 A2+, A3+ A2, A3 51N+ 43N+        5.6 13.1    94.3 86.8
Holmes [34] I, II 53 0 58 A2+, A3+   27N+   NA 99.4    0.3 0.99       
Patil [22] I, II 106 81 56 A2+, A3+ A2, A3 46N+ 53N+ 3 14 3.2 3.5    8.3 14.8     
Gates [35] I 24 22 63 A2+ A2    5 31.5 1.6 9.7    28.6 26.3 95.2 100   
Benavides [36] II 85 66 54 A2+, A3+ A2, 49N+ 42N+ 4 14.84 NA 1.1 0.73 1.83 11.7 18.2 98.8 92.42   
Peoples [20] II 101 85 57 A2+, A3+ A2, A3 45N+ 46N+ 0.5 14 1.4 2.1 0.39 1.8 5.6 14.2 99 95.1 92.5 77
Holmes [23] II 99 0   A2+, A3+   48N+   2.7 21.5    0.416 1.78 10.1      
Amin [27] II 101 85   A2+, A3+ A2, A3 45N+ 46N+ 12.8 13.625 NA 2.64 0.42 1.79 8.3 14.8 99 93.8 88 58
Stojadinovic [37] I 16 NA 52 A2+   16N+   NA 22.3 NA 3 0.36 0.65       
Dehqanzada [38] I, II 36 0 59.7 A2+ A2 12N+              
Dehqanzada [39] I, II 32 0 57 A2+   10N+              
Hueman [40] II 7 17   A2+ A2 7N 17N      58.8 67.4       
Hueman [41] I 22 22   A2+ A2 22N 22N      0.75 1.2       
Mittendorf [42] I 44 0   A2+ A2 24N+       0.5 1.68       
Peoples [21] I 24 29   A2+ A2 24N+ 29N+ NA 33 NA 7 0.56 1.66 8.3 20.7 100 93 85.7 59.8
Murray [43] I 13 0 48 A2+   6N+   NA 7.83           
Knutson [44] I 4 10 48 A2+ A2+               
E75 Total 21 trials   1580 1156                  
  1. NA not available, DTH delayed hypersensitivity reaction, HLA human leukocyte antigen, DTH delayed-type hypersensitivity reaction, DFS disease-free survival rate, HLA-A2± A2± human leukocyte antigen A2 positive/negative, HLA-A3± A3± human leukocyte antigen A3 positive/negative , HLA-A24± A24± human leukocyte antigen A24 positive/negative, HLA-A26± A26± human leukocyte antigen A26 positive/negative
  2. aTommy A(2020) and Mittendorf EA(2016) 17reported the same clinical trial